AngioDynamics gets FDA OK for prostate cancer study

06/20/2013 | MedGadget.com

AngioDynamics has received investigational device exemption approval from the FDA to conduct a clinical study of its NanoKnife technology, which uses precise ablation to treat patients with localized prostate cancer. The trial will enroll 200 patients from six clinical sites in Europe.

View Full Article in:

MedGadget.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI